Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Neonatal Care Unit receives donation to expand capacity
2015-10-28

  

With the best care and technology available,
the survival rate of premature
babies is about 85%. The neonatal intensive
care unit at the Universitas hospital can now
expand its capacity thanks to a donation of
R1 million by the Discovery fund.
From the left is Prof André Venter.
Head: Department of Paediatrics and
Child Health at the UFS, and mrs Ruth Lewin,
Head: Corporate Sustainability at Discovery. 

The smallest people need the greatest care. This care is being provided by the neonatal unit in the Children’s Wing of the Universitas Hospital. This project of the University of the Free State (UFS), under the leadership of Prof Andre Venter, has led to several miracles regarding child health since its inception.

Now, thanks to a donation of R1 million rand from the Discovery fund, this unit can expand its capacity and treat more premature babies.

About 14% of babies in South Africa are born before the 37th week of pregnancy. These babies are born with a very low birth weight, and are in need of critical care. The neonatal intensive-care unit at Universitas Hospital is currently equipped to take care of about 14 premature babies at a time, from birth to discharge. However, because of the high incidence of premature births in the hospital’s service area, the unit needs about 45 beds.

The aim of the Children’s Wing Project is to expand the neonatal intensive-care unit in order to meet the demands of the hospital’s service area, which reaches as far as the Southern Cape. The Discovery Fund recently donated R1 million to the project, which will be used to expand the capacity of the neonatal intensive-care unit.

“With the best care and technology available, the survival rate of premature babies is about 85%. Without this, half of all premature babies would die,” says Prof Venter, Head: Department of Paediatrics and Child Health at the UFS.

“This is the reason why private and public partnerships, such as the one with Discovery, are essential to make specialised services available to the most vulnerable people. Discovery has made a significant contribution to the project without which we would not have been able to expand the capacity of the unit



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept